臨床外科69巻1号

2014年01月発行

特集 見直される膵癌診療の新展開

治療における新展開―切除不能例への治療戦略

ペプチドワクチンを用いた膵癌治療

著者： 谷眞至¹ 山上裕機¹

所属機関： ¹和歌山県立医科大学第2外科

ページ範囲：P.64 - P.69

文献概要

【ポイント】

◆ペプチドワクチンは直接癌細胞を傷害しないが，リンパ球などの効果細胞を介して標的とする部位が明らかになっていることから，理論的根拠に基づいたペプチドワクチン療法の開発が可能である．

◆自然発癌において，腫瘍細胞は宿主免疫監視機構をすり抜けて発育していることから，様々な免疫逃避機構の存在に関する推測ができる．

◆今後，新しいペプチドの同定ならびにワクチンアジュバントの開発など，解決しなければならない問題が山積しており，さらなる治験などの臨床試験の推進が必要である．

参考文献

1）日本膵臓学会：膵癌登録報告2007．膵臓22：e1-e429, 2007

2）Burris HA 3rd, Moore MJ, Andersen J, et al：Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer：a randomized trial. J Clin Oncol 15：2403-2413, 1997

3）Moore MJ, Goldstein D, Hamm J, et al：Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer：a phaseⅢ trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25：1960-1966, 2007

4）Vaccaro V, Sperduti I, Milella M：Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 365：768-769, 2011

5）Rosenberg SA, Lotze MT, Yang JC, et al：Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85：622-632, 1993

6）Tani M, Tanimura H, Yamaue H, et al：In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. Eur J Clin Pharmacol 42：623-627, 1992

7）Yamaue H, Tanimura H, Iwahashi M, et al：Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432. Cancer Immunol Immunother 29：79-86, 1989

cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer 60：802-807, 1995

9）Rosenberg SA, Spiess P, Lafreniere R：A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233：1318-1321, 1986

10）Van Der Bruggen P, Traversari C, Chomez P, et al：A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254：1643-1647, 1991

11）Galon J, Costes A, Sanchez-Cabo F, et al：Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313：1960-1964, 2006

12）Von Hoff DD, Ervin TJ, Arena FP：Randomized phaseⅢ study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas（MPACT）. J Clin Oncol 31 （suppl）：abstr LBA148, 2013

13）Khong HT, Restifo NP：Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3：999-1005, 2002

14）Ryschich E, Notzel T, Hinz U, et al：Control of T-cell-mediated immune response by HLA classⅠ in human pancreatic carcinoma. Clin Cancer Res 11：498-504, 2005

15）Marincola FM, Jaffee EM, Hicklin DJ, et al：Escape of human solid tumors from T-cell recognition：molecular mechanisms and functional significance. Adv Immunol 74：181-273, 2000

16）Garrido F, Algarra I, Garcia-Lora AM：The escape of cancer from T lymphocytes：immunoselection of MHC classⅠ loss variants harboring structural-irreversible “hard” lesions. Cancer Immunol Immunother 59：1601-1606, 2010

17）Ishigami S, Natsugoe S, Nakajo A, et al：HLA-classⅠ expression in gastric cancer. J Surg Oncol 97：605-608, 2008

18）Tsukahara T, Kawaguchi S, Torigoe T, et al：Prognostic significance of HLA classⅠ expression in osteosarcoma defined by anti-pan HLA classⅠ monoclonal antibody, EMR8-5. Cancer Sci 97：1374-1380, 2006

19）Kitamura H, Torigoe T, Asanuma H, et al：Down-regulation of HLA classⅠ antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol 178：692-696, 2007

20）Teicher BA：Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 13：6247-6251, 2007

21）Ichihara F, Kono K, Takahashi A, et al：Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9：4404-4408, 2003

22）Folkman J：Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1：27-31, 1995

23）Li Y, Wang MN, Li H, et al：Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195：1575-1584, 2002

24）Wada S, Tsunoda T, Baba T, et al：Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 65：4939-4946, 2005

25）Ishizaki H, Tsunoda T, Wada S, et al：Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 12：5841-5849, 2006

26）Itakura J, Ishiwata T, Friess H, et al：Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 3：1309-1316, 1997

27）Seo Y, Baba H, Fukuda T, et al：High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88：2239-2245, 2000

28）Miyazawa M, Ohsawa R, Tsunoda T, et al：PhaseⅠ clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 101：433-439, 2010

29）Yamaue H, Tani M, Miyazawa M, et al：PhaseⅡ/Ⅲ clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with locally advanced, metastatic, or unresectable pancreatic cancer：Pegasus-PC Study. J Clin Oncol 30 （suppl 34）： abstr 223, 2013

30）Zucker DM, Yang S：Inference for a family of survival models encompassing the proportional hazards and proportional odds models. Stat Med 25：995-1014, 2006

31）O'day SJ, Maio M, Chiarion-Sileni V, et al：Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma：a multicenter single-arm phaseⅡ study. Ann Oncol 21：1712-1717, 2010

32）Wolchok JD, Hoos A, O'day S, et al：Guidelines for the evaluation of immune therapy activity in solid tumors：immune-related response criteria. Clin Cancer Res 15：7412-7420, 2009

33）Kono K, Iinuma H, Akutsu Y, et al：Multicenter, PhaseⅡ clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 10：141, 2012

34）Butterfield LH, Palucka AK, Britten CM, et al：Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 17：3064-3076, 2011

35）Disis ML：Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 60：433-442, 2011

T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 101：2510-2517, 2010

37）Kantoff PW, Higano CS, Shore ND, et al：Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363：411-422, 2010